TScan Therapeutics Engages Investors at Key Upcoming Events
TScan Therapeutics Engages Investors at Key Upcoming Events
TScan Therapeutics, Inc. (Nasdaq: TCRX), a pioneering clinical-stage biotechnology company, is excited to announce its participation in a series of significant investor conferences. Focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies, TScan is dedicated to offering groundbreaking solutions for cancer treatment.
What to Expect from Upcoming Conferences
At the Morgan Stanley 23rd Annual Global Healthcare Conference, set for September 9, 2025, a fireside chat will take place at the Sheraton New York Times Square at 5:35 p.m. ET. This event will provide an important platform for discussions surrounding the future of TCR-T therapies.
Details of Additional Conference Participation
Another major highlight will be at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025, at the Lotte New York Palace Hotel, where TScan will present at 9:00 a.m. ET. These conferences are pivotal moments for TScan to connect with investors and share their latest advancements.
Accessing Presentations and Webcasts
For those unable to attend in person, TScan Therapeutics will make webcasts of these events available. Interested parties can find them under the "Events and Presentations" section of the company’s website, where archived replays will also be accessible for 90 days post-event. This ensures that information about TScan's progress and innovations can reach a wider audience.
Insight into TScan Therapeutics
TScan is committed to advancing the field of oncology with its innovative TCR-T therapies. The company’s lead candidates are currently under development, aimed at treating hematologic malignancies while preventing relapse following allogeneic hematopoietic cell transplantation. This aligns perfectly with the company’s overarching goal to provide customized solutions for patients.
The Importance of the ImmunoBank
One of the key assets of TScan is its ImmunoBank, a comprehensive repository of therapeutic TCRs. These TCRs are tailored to recognize a diverse range of targets associated with multiple HLA types, enabling TScan to offer customized multiplex TCR-T therapies for various cancer types. The ongoing trials, including the ALLOHA Phase 1 heme trial and the PLEXI-T Phase 1 solid tumor trial, emphasize TScan's dedication to innovative cancer treatments.
Contact Information for Investor Relations
For more information, investors can reach out to TScan Therapeutics through their VP of Investor Relations, Heather Savelle, at 857-399-9840 or via email. Additionally, Melissa Forst from Argot Partners is available for inquiries. Their dedication to transparency keeps investors well-informed about company initiatives and advancements.
Frequently Asked Questions
1. What is TScan Therapeutics known for?
TScan Therapeutics is recognized for its development of TCR-engineered T cell therapies aimed at treating cancer patients.
2. When are the upcoming investor conferences?
Key conferences will take place on September 9 and September 10, 2025, in New York City.
3. How can I access the webcasts from the conferences?
Webcasts will be available on the "Events and Presentations" section of TScan's website for 90 days after the events.
4. What is the ImmunoBank?
The ImmunoBank is TScan's repository of therapeutic TCRs that allows for customized TCR-T therapies for various cancer types.
5. Who can I contact for more information about TScan?
For additional details, you can contact Heather Savelle at TScan or Melissa Forst at Argot Partners.
About The Author
Contact Caleb Price privately here. Or send an email with ATTN: Caleb Price as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
